ABOUT: NovAccess Global is a biomedical company accelerating novel cancer diagnostics and therapeutics and is currently developing a cancer vaccine therapy that enhances the patient’s immune response against brain tumors. They offer a novel immunotherapeutic approach to treating brain tumor patients with glioblastoma, the most common adult brain tumor with a 15-month median survival after diagnosis. Their patented technology is designed to combine a dendritic cell-based immunotherapeutic approach to help promote an enhanced immune response against the patient’s tumor. For more information, please visit novaccessglobal.com.
THIS INTERVIEW HAS EXPIRED